MedTrace Logo

Study of PXL065 in Patients With Nonalcoholic Steatohepatitis (NASH)

NCT04321343 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 117

Last updated 2023-08-29

Study results available
· View outcomes & findings →

Summary

This study will assess the effect of 3 doses of PXL065 versus placebo on liver fat content in NASH patients after 36 weeks of treatment

Conditions

  • NASH - Nonalcoholic Steatohepatitis

Interventions

DRUG

PXL065

PXL065 oral tablet

DRUG

Placebo oral tablet

Placebo oral tablet

Sponsors & Collaborators

  • Poxel SA

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-01
Primary Completion
2022-06-08
Completion
2022-06-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04321343 on ClinicalTrials.gov